Message-ID:

BOFH excuse #252: Our ISP is having {switching,routing,SMDS,frame relay} problems

sci / sci.med.pathology / Iron Chelation In Myelodyspastic Syndrome

Subject: Iron Chelation In Myelodyspastic Syndrome
From: ironjustice
Newsgroups: sci.med.pathology
Date: Wed, 30 Oct 2019 11:27 UTC

X-Received: by 2002:a0c:aac2:: with SMTP id g2mr28620600qvb.205.1572434855923; Wed, 30 Oct 2019 04:27:35 -0700 (PDT)
X-Received: by 2002:a81:8203:: with SMTP id s3mr21899811ywf.396.1572434855693; Wed, 30 Oct 2019 04:27:35 -0700 (PDT)
Path: eternal-september.org!news.eternal-september.org!reader01.eternal-september.org!reader01.eternal-september.org!feeder.eternal-september.org!feeder1.usenet.farm!feed.usenet.farm!feeder.usenetexpress.com!tr2.iad1.usenetexpress.com!border1.nntp.dca1.giganews.com!nntp.giganews.com!j16no3465932qtl.0!news-out.google.com!d16ni463qtp.0!nntp.google.com!j16no3465927qtl.0!postnews.google.com!glegroupsg2000goo.googlegroups.com!not-for-mail
Newsgroups: sci.med.pathology
Date: Wed, 30 Oct 2019 04:27:35 -0700 (PDT)
Complaints-To: groups-abuse@google.com
Injection-Info: glegroupsg2000goo.googlegroups.com; posting-host=2001:56a:723e:aa00:2859:4ce0:63f8:fb6; posting-account=hBAG4AoAAABOaauYJdMbCKnI-qYy_97e
NNTP-Posting-Host: 2001:56a:723e:aa00:2859:4ce0:63f8:fb6
User-Agent: G2/1.0
MIME-Version: 1.0
Message-ID: <43e22da4-96f9-479d-9b0a-3bb3731e8aec@googlegroups.com>
Subject: Iron Chelation In Myelodyspastic Syndrome
From: teamtanner@hotmail.com (ironjustice)
Injection-Date: Wed, 30 Oct 2019 11:27:35 +0000
Content-Type: text/plain; charset="UTF-8"
Content-Transfer-Encoding: quoted-printable
Lines: 50

View all headers

Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy.
Rodríguez-García A1, Morales ML2, Garrido-García V3, García-Baquero I4, Leivas A5, Carreño-Tarragona G6, Sánchez R7, Arenas A8, Cedena T9, Ayala RM10, Bautista JM11, Martínez-López J12,13, Linares M14,15.
Antioxidants (Basel). 2019 Oct 24;8(11). pii: E508. doi: 10.3390/antiox8110508.

Abstract
Control of oxidative stress in the bone marrow (BM) is key for maintaining the interplay between self-renewal, proliferation, and differentiation of hematopoietic cells. Breakdown of this regulation can lead to diseases characterized by BM failure such as the myelodysplastic syndromes (MDS). To better understand the role of oxidative stress in MDS development, we compared protein carbonylation as an indicator of oxidative stress in the BM of patients with MDS and control subjects, and also patients with MDS under treatment with the iron chelator deferasirox (DFX). As expected, differences in the pattern of protein carbonylation were observed in BM samples between MDS patients and controls, with an increase in protein carbonylation in the former. Strikingly, patients under DFX treatment had lower levels of protein carbonylation in BM with respect to untreated patients. Proteomic analysis identified four proteins with high carbonylation levels in MDS BM cells. Finally, as oxidative stress-related signaling pathways can modulate the cell cycle through p53, we analyzed the expression of the p53 target gene p21 in BM cells, finding that it was significantly upregulated in patients with MDS and was significantly downregulated after DFX treatment. Overall, our results suggest that the fine-tuning of oxidative stress levels in the BM of patients with MDS might control malignant progression.

KEYWORDS:
carbonylation; deferasirox; myelodysplastic syndromes; oxidative stress

PMID: 31652983 DOI: 10.3390/antiox8110508
Free full text

Who loves ya.
Tom

Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh

Man Is A Herbivore!
http://tinyurl.com/4rq595

DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk

Subject	Author
Iron Chelation In Myelodyspastic Syndrome	ironjustice